1Yao M, Kargrnan S, Lain EC, et al. Inhibition of Cyclooxygenase -2 by Rofecoxib Attenuates the Growth and Metastatic Potential of Colorectal Carcinoma in Mice.Cancer Res, 20031 63(3): 586-592.
2Zhou Y, Su Y, Li B, et al. Nonsteroidal Anti -Inflammatory Drugs Can Lower Amyloidogenic A 42by Inhibiting Rho. Science, 2003,302(5648): 1215- 1217.
4Hawkey C J, Langman M J, Non - steroidal anti - inflammatory drugs: overall risks and management. Complementary roles for COX -2 inhibitors and proton pump inhibitors. Gut ,2003 ,52 (4) : 600 - 608.
1Kim JG, Graham DY. Helicobacter pylori infection and development of gastric or duodenal ulcer in arthritic patients receiving chronic NSAIDs therapy. The misoprostol study group. Am J Gastroenterol,1994, 89:203-207.
2Wu CY, Poon SK, Chen GH, et al. Interaction between Helicobacter pylori and non-steroidal anti-inflammatory drugs in peptic ulcer bleeding. Scand J Gastroenterol, 1999,34:234-237.
3Weil J, Colin-Jones D, Langnan M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ, 1995,310:827-830.
4Soll A . Pathogenesis of non-steroidal anti-inflammatory drugs-related upper gastrointestinal toxicity. Am J Med, 1998,105 (SA) :10S-16S.
5Cryer B, Redfem JS, Goldschmiedt M, et al. Effect of aging on gastric and duodenal mucosal prostaglandin concentrations in humans. Gastroenterology, 1992,102(4 Pt 1) :1118-1123.
6Aalykke C, Lauritsen JM, Hallas J, et al. Helicobacter pylori and risk of ulcer bleeding among user of non-steroidal anti-inflammatory drugs: a case-control study. Gastroenterology, 1999, 116: 1305-1309.
7Chong Y Y，Ann Acad Med Singapore，1996年，25卷，496页
8Laporte J R，Lancet，1991年，337卷，85页
9FDA announces a series of changes to the class of marketed non-steroidal anti-inflammatory drugs (NSAIDs). www. fda.gov/bbs/topics/news/2005/NEW01171. html , 2005-04-07/2005 -05.
